Baxfendy Approved in the U.S. as the First and Only Aldosterone Synthase Inhibitor Treatment for Adults With Hypertension
May 20, 2026
May 20, 2026
WILMINGTON, Delaware, May 20 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with
uncontrolled or resistant hypertension
BAXF . . .
* * *
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
Approval based on BaxHTN Phase III results showing statistically significant and clinically meaningful reduction in systolic blood pressure in patients with
uncontrolled or resistant hypertension
BAXF . . .